# Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)

> **NCT06474520** · NA · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 250 (estimated)

## Conditions studied

- Idiopathic Inflammatory Demyelinating Disease
- Multiple Sclerosis
- Neuromyelitis Optica Spectrum Disorder
- Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Acute Disseminated Encephalomyelitis

## Interventions

- **DRUG:** Calculus bovis sativus (CBS)

## Key facts

- **NCT ID:** NCT06474520
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-08
- **Primary completion:** 2029-07
- **Final completion:** 2029-12
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2024-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06474520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06474520, "Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06474520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*